Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia

NCT07722767 is registered in ClinicalTrials.gov with Cullinan Therapeutics Inc. as lead sponsor.

NCT NCT07722767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07722767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia
Lead sponsor
Cullinan Therapeutics Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
August 31, 2030
Enrollment
90 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myeloid leukemia)